ArticleFrontiers in oncology2025
Hepatic involvement as an initial manifestation of multiple myeloma: a case report with atypical imaging features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolically Silent Diffuse Hepatic Involvement in Multiple Myeloma: AnMolecular imaging and radionuclide therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic involvement as the initial manifestation of multiple myeloma (MM) is exceedingly rare and presents significant diagnostic challenges due to its heterogeneous imaging features, which often mimic metastatic liver tumors. We report a case of a 62-year-old man presenting with right upper quadrant discomfort. Imaging revealed a hypoechoic lesion in segment II of the liver on ultrasound, a low-density area with mild enhancement on contrast-enhanced CT, and atypical MRI features including hyperintensity on T1- and T2-weighted images, mild diffusion restriction on diffusion-weighted imaging (DWI), and minimal enhancement post-Gd-DTPA administration. Histopathology demonstrated diffuse infiltration of atypical plasma cells consistent with plasmacytoma, supported by immunohistochemical positivity for CD138, CD38, MUM1, and CD56, and an elevated serum β
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.